4.7 Article

Role of Protease-activated Receptor-2 in Idiopathic Pulmonary Fibrosis

Journal

Publisher

AMER THORACIC SOC
DOI: 10.1164/rccm.201009-1479OC

Keywords

protease activated receptor-2; idiopathic pulmonary fibrosis; coagulation factor VII; tissue factor

Funding

  1. German Research Foundation (DFG) [KFO 118]
  2. Excellence Cluster Cardiopulmonary System (ECCPS)
  3. University Medical Center Giessen and Marburg (UKGM)
  4. European Commission
  5. German Ministry of Education and Research (German Network for Diffuse Parenchymal Lung Diseases)
  6. University Medical Center Giessen and Marburg
  7. Excellence Cluster Cardiopulmonary System
  8. German Ministry of Education and Research
  9. Actelion
  10. Pfizer
  11. Novartis
  12. InterMune
  13. Nycomed
  14. Activaero
  15. Marburg

Ask authors/readers for more resources

Rationale: Activation of the coagulation cascade has been demonstrated in pulmonary fibrosis. In addition to its procoagulant function, various coagulation proteases exhibit cellular effects that may also contribute to fibrotic processes in the lung. Objective: To investigate the importance of protease-activated receptor (PAR)-2 and its activators, coagulation factor VIIa (FVIIa)/tissue factor (TF), in the development of idiopathic pulmonary fibrosis (IPF). Methods: Expression and localization of PAR-2 and its activators were examined in IPF lung tissue. The ability of PAR-2 to mediate various cellular processes was studied in vitro. Measurements and Main Results: Expression of PAR-2 was strongly elevated in IPF lungs and was attributable to alveolar type II cells and fibroblasts/myofibroblasts. Transforming growth factor-b1, a key profibrotic cytokine, considerably enhanced PAR-2 expression in human lung fibroblasts. FVIIa stimulated proliferation of human lung fibroblasts and extracellular matrix production in a PAR-2dependent manner, but did not initiate differentiation of fibroblasts into myofibroblasts. PAR-2/FVIIa-driven mitogenic activities were mediated via the p44/42 mitogen-activated protein kinase pathway and were independent of factor Xa and thrombin production. Proproliferative properties of FVIIa were markedly potentiated in the presence of TF and abrogated by TF antisense oligonucleotides. Hyperplastic alveolar type II cells overlying fibroblastic foci were found to be the source of FVII in IPF lungs. Moreover, TF colocalized with PAR-2 on fibroblasts/myofibroblasts in IPF lungs. Conclusions: The PAR-2/TF/FVIIa axis may contribute to the development of pulmonary fibrosis; thus, interference with this pathway confers novel therapeutic potential for the treatment of IPF.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available